The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL

CONCLUSION: Our results indicate good safety and efficacy for single-agent ibrutinib in R/R CLL in daily practice.PMID:34629286 | DOI:10.1016/j.clml.2021.09.010
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Source Type: research